Observational studyMedicine2025
Impact of chemotherapy on sexual dysfunction in Turkish women with breast cancer: A single-center prospective cohort study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although numerous studies have explored the connection between breast cancer surgery and sexual function, research on chemotherapy's temporal effects is limited. Addressing the impact of chemotherapy on sexual dysfunction is critical for improving quality of life. The aim of this study is to investigate changes in sexual function before, during, and after chemotherapy treatment, with a focus on associated factors. A total of 101 sexually active, reproductive-aged women diagnosed with locally advanced breast cancer were included in the study. The sexual dysfunction was evaluated by using the female sexual function index (FSFI) across 3 treatment phases: before, during, and after chemotherapy. Covariates such as age, baseline sexual dysfunction, tumor localization, comorbidity, family history of cancer, and receptor-related factors were analyzed for their influence on score changes during specific periods. A mixed-effects model was employed to evaluate associations and interactions between these variables and sexual function outcomes. Sexual function scores significantly declined across treatment phases. Notable reductions were observed in desire (P < .001), arousal (P < .001), lubrication (P < .001), orgasm (P < .01), and satisfaction (P < .01), while pain scores increased (P < .01). Total FSFI scores significantly dropped during and after chemotherapy (P < .001 and P < .01, respectively). Patients with preexisting sexual dysfunction experienced significantly greater declines in desire, lubrication, and satisfaction, along with more pronounced increases in pain-related discomfort scores, particularly in the FSFI pain subscale (P < .01). Older age, comorbidity, and tumor localization were significantly associated with worsening sexual function, whereas receptor status and histopathology showed no meaningful effect. Our findings confirm a high prevalence of sexual dysfunction among women with breast cancer. These results highlight the multifaceted impact of chemotherapy on sexual function and reveal a clear temporal pattern of changes across treatment phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.